Soo Bang, Sr. Vice President of K36 Therapeutics, where she leads Strategy and Operations for private biotech company developing epigenetic small molecule for multiple myeloma and other solid tumors. Previously, Soo founded Integration Alliance Partners, a private consulting company that shapes, grows, and builds biotech companies to bring innovative therapies to market. Before her consulting role, Soo led the largest biotech and pharma integration as VP, Enterprise Integration Management at BMS, leading the $74 billion Celgene integration across key milestones, strategic planning of markets and integration activities. At Celgene, Soo built an 8-year career in a range of growing responsibilities, most recently, as VP of Business Strategy, Integration & Planning for the Global Pharmaceutical Development & Operations, where she had overall responsibility for the project management, operational excellence, EHS, technical commercialization and alliance management teams. Soo spent 4-years as the Executive Director, Business Development & Global Alliances, where she managed alliance relationships across Hem/Onc, I&I and Early Development, and was the BD and alliance lead for numerous collaborations with clinical programs in both biologics and small molecules, including notable acquisition of two latestage oncology and hematology assets and program out licensing. Prior to the BD role, she was the Global Head of Clinical Site Contracts, where she led a global team responsible for study start-up activities. Before Celgene, Soo served as the Face of Pfizer, as the Global Investigator Lead, responsible for contract and outsourcing across all BUs, and medical affairs. She also held various leadership positions at Medstar Research Institute, NYC Health & Hospitals Corp, Director of Clinical Trials at NYU Medical Center, and Winthrop University. Soo received her B.A. and M.S. from George Washington University and completed her administrative fellowship at Johns Hopkins Health System. Soo has been a passionate partner with several Patient Advocacy groups in brain tumor research groups, LLS and PanCAN. She is also actively involved in the career development of others by leading mentorship programs within Celgene, Society of Neuro-Oncology Women & Diversity Committee, Women Leaders in Oncology at ASCO and the Healthcare Businesswomen’s Association. functional service providers, and medical affairs. She also held various leadership positions at NYC Health & Hospitals Corp, Director of Clinical Trials at NYU Medical Center, and Winthrop University Health System. Soo also served as industry lead for the “Advancing the use of Central IRBs” for the Clinical Trials Transformation Initiative, a private public initiative with the FDA. Soo received her B.A. and M.S. from George Washington University and completed her administrative fellowship at Johns Hopkins Health System. Soo is a certified Alliance Management Professional and has a green belt in Lean Six Sigma. Soo has been a passionate partner with several Patient Advocacy groups in brain tumor research groups, LLS and PanCAN. She is also actively involved in the career development of others by leading mentorship programs within Celgene, Society of Neuro-Oncology Women & Diversity Committee, Women Leaders in Oncology at ASCO and the Healthcare Businesswomen’s Association.
Soo Bang, MHSA, CA-AM